What one share of Addex Therapeutics holds
We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises of a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partner and internally.
Addex Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.00 |
|---|---|
| Profit | −$0.45 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.15 |
| Cash and investments | $0.08 |
| Debt | $0.00 |
| Book value | $0.24 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$1.55 | $0.00 | −$1.01 | — | $0.62 |
| 2018 | $1.59 | −$0.43 | $0.00 | $0.46 | — | $9.07 |
| 2019 | $0.63 | −$3.38 | $0.01 | −$2.17 | — | $5.95 |
| 2020 | $0.87 | −$3.08 | $0.01 | −$2.93 | — | $3.66 |
| 2021 | $0.56 | −$2.95 | $0.01 | −$2.83 | — | $2.93 |
| 2022 | $0.20 | −$2.90 | $0.00 | −$2.29 | — | $0.41 |
| 2023 | $0.15 | −$0.95 | $0.00 | −$0.72 | — | $0.07 |
| 2024 | $0.03 | $0.49 | $0.00 | −$0.37 | — | $0.50 |
| 2025 | $0.00 | −$0.45 | $0.00 | −$0.15 | — | $0.24 |
Common questions about Addex Therapeutics
How much does one share of Addex Therapeutics earn?
Over its latest fiscal year, Addex Therapeutics lost $0.45 for each share on $0.00 of sales.
Does Addex Therapeutics pay a dividend?
Addex Therapeutics didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is Addex Therapeutics’s book value per share?
Addex Therapeutics’s book value is $0.24 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of Addex Therapeutics have?
Each share of Addex Therapeutics has $0.08 of cash and investments and $0.00 of debt, as of December 31, 2025.
What is Addex Therapeutics’s free cash flow per share?
−$0.15 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has Addex Therapeutics bought back shares?
Addex Therapeutics’s share count rose about 730% from 2017 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.